Compare Illumina, Inc. (ILMN) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Illumina, Inc. trades at $190.91 (market cap $29.12B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $60. Which is the better fit depends on your goals.
| ILMN | JEPQ | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $205.10 | $61.46 |
52-Week Low | $91.00 | $53.77 |
Enterprise Value | $30.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
JEPQ trades at $60.055, up 0.63% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates consistent monthly income, with recent dividends of $0.70, $0.64, and $0.56. News coverage highlights its role in retirement income strategies alongside tax considerations for distributions. Institutional interest remains strong with Bank of America increasing its stake by 8.9% in Q1 2026.
JEPQ offers attractive yield generation through its Nasdaq-focused options strategy, but investors face tax implications as distributions are taxed as ordinary income. The ETF's performance depends on market volatility for premium collection, creating both opportunity and risk during turbulent periods. Current technical strength supports near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
